Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Eunkyung A, Kauh"'
Autor:
Dhananjay D. Marathe, Petra M. Jauslin, Huub Jan Kleijn, Carolina deMiranda Silva, Anne Chain, Thomas Bateman, Peter M. Shaw, Anson K. Abraham, Eunkyung A. Kauh, Yanfang Liu, Rodolfo F. Perini, Dinesh P. deAlwis, Lokesh Jain
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 10, Pp 1499-1510 (2023)
Abstract Belzutifan (Welireg, Merck & Co., Inc., Rahway, NJ, USA) is an oral, potent inhibitor of hypoxia‐inducible factor 2α, approved for the treatment of certain patients with von Hippel–Lindau (VHL) disease‐associated renal cell carcinoma
Externí odkaz:
https://doaj.org/article/9fb57ee9c9224d38a940c36af9575776
Autor:
Douglas G. Johns, Louis-Charles Campeau, Puja Banka, An Bautmans, Tjerk Bueters, Elisabetta Bianchi, Danila Branca, Paul G. Bulger, Inne Crevecoeur, Fa-Xiang Ding, Robert M. Garbaccio, Erik D. Guetschow, Yan Guo, Sookhee N. Ha, Jennifer M. Johnston, Hubert Josien, Eunkyung A. Kauh, Kenneth A. Koeplinger, Jeffrey T. Kuethe, Eseng Lai, Christine L. Lanning, Anita Y.H. Lee, Li Li, Anilkumar G. Nair, Edward A. O’Neill, S. Aubrey Stoch, David A. Thaisrivongs, Thomas J. Tucker, Petr Vachal, Kristien van Dyck, Frederic P. Vanhoutte, Bram Volckaert, Dennis G. Wolford, Andy Xu, Tian Zhao, Dan Zhou, Susan Zhou, Xiaohong Zhu, Hratch J. Zokian, Abbas Walji, Harold B. Wood
Publikováno v:
Circulation.
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite
Autor:
Carol, Addy, Daniel A, Tatosian, Xiaoli S, Glasgow, Isaias Noel, Gendrano, Christine McCrary, Sisk, Eunkyung A, Kauh, S Aubrey, Stoch, John A, Wagner
Publikováno v:
Clinical pharmacology in drug development. 5(5)
Omarigliptin is being developed as a potent, once-weekly, oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. This double-blind, randomized, placebo-controlled study evaluated the effects of age, sex, and obesity on the pharma
Publikováno v:
Journal of Biological Chemistry. 272:12091-12099
The antineoplastic alkaloid camptothecin interferes with the catalytic cycle of DNA topoisomerase I rendering it a cellular poison. Camptothecin stabilizes a covalent enzyme-DNA intermediate that is converted into lethal double strand DNA lesions dur
Autor:
Mary-Ann Bjornsti, Eunkyung A. Kauh
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 92(14)
Camptothecin is a potent antineoplastic agent that interferes with the action of eukaryotic DNA topoisomerase I; the covalent enzyme-DNA intermediate is reversibly stabilized, leading to G2 arrest and cell death. We used a genetic screen to identify
Autor:
Michael J. Fazio, Zena K. Indik, Joel Rosenbloom, Eunkyung A. Kauh, Clinton T. Baldwin, Jouni Uitto, David R. Olsen, Norma Ornstein-Goldstein, Helena Yeh
Publikováno v:
Journal of Investigative Dermatology. 91(5):458-464
A human cDNA library was constructed utilizing RNA isolated from cultured skin fibroblasts. Recombinant clones containing elastin sequences were identified by plaque hybridizations with previously characterized human placental elastin cDNAs. Seven po